While the relationship between CD133 expression and colorectal tumor volume or stage varies among studies (30, 31, 65), a meta-analysis of 27 tumorgenicity studies found a twofold increase in tumor volume in cells that expressed CD133 or CD44. This evidence concerns the gene PROM1 and colorectal neoplasm.